In the decision-making process for the treatment of metastatic urothelial carcinoma and locally advanced urothelial carcinoma, HER2-targeted antibody–drug conjugates and immune checkpoint inhibitors have entered the scope of international guidelines such as EAU and NCCN [11,12]. Here, ERBB2 is linked to urothelial carcinoma.